Boehringer Ingelheim India has entered into a strategic partnership with Vvaan Lifesciences Pvt Ltd to distribute its pet parasiticide portfolio in Tier 2 cities of the country. The collaboration, an initiative under Boehringer Ingelheim India’s animal health accelerated growth plan, marks a significant step in expanding the company’s reach and enhancing customer value in the animal health sector.
India’s pet health market is currently worth around €115 million ($129 million, or Rs1,078 crore). According to Boehringer Ingelheim India’s internal estimates, metropolitan and Tier 1 cities contribute approximately 60% of overall revenues, with the rest coming from Tier 2 and smaller cities.
In its mission to advance animal health, the partnership will leverage the expertise of Vvaan Lifesciences, a company with extensive experience in the animal health industry, particularly the dairy and poultry industries, to extend the reach of Boehringer Ingelheim India’s pet portfolio in Tier 2 cities. The collaboration aims to meet the growing demand in mini metros, expand the company’s customer base in underserved regions, and improve veterinary care standards across India.
Also Read: German pharma company introduces broad-spectrum tablet for parasite control in pet dogs
Dr Vinod Gopal, country head for animal health, Boehringer Ingelheim India, said, “At Boehringer Ingelheim, we are deeply committed to making our innovative, high-quality medications accessible to all, regardless of geographical location. We understand the unique challenges faced by non-metro and rural communities in accessing quality healthcare for pet parents and their pets. Our strategic partnership with Vvaan Lifesciences is a significant step towards bridging this gap.”
Dr Maneesh Jain, director and chief executive officer, Vvaan Lifesciences Pvt Ltd, said, “We are excited about this partnership with Boehringer Ingelheim. Our strong presence in Tier 2 cities, combined with Boehringer Ingelheim’s innovative pet parasiticide products, will significantly improve the availability and quality of pet healthcare across India. We look forward to working together to make a positive impact on the lives of pets and pet parents in these regions, with the support of vets.”
Vvaan Lifesciences is an animal health company that has a team of professionals with decades of experience across the dairy, poultry, and companion animal segments. The company aims to provide the best, innovative and quality products to the dairy and poultry farmer, which help to improve their productivity and profitability.
Boehringer Ingelheim, a leading biopharmaceutical company founded in Germany in 1885, develops breakthrough therapies for humans and animals. With 53,000 employees, it operates in over 130 markets, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing.
Established in 2003, Boehringer Ingelheim India manages operations in India and neighbouring markets, offering innovative products in human pharmaceuticals and animal health, with key therapy areas including diabetes, cardiovascular, and respiratory conditions.
SOURCE: PR Newswire
Caution: Information in news reports, press releases, or articles on TheSnout.in is not intended to serve as a medical opinion or advice. Do not attempt to treat yourself or your pets without consulting the appropriate medical professional.
